AFF3 Pre-design Chimera RNAi
- Known as:
- AFF3 Pre-design Chimera RNAi
- Catalog number:
- H00003899-R02
- Product Quantity:
- 10 nmol
- Category:
- -
- Supplier:
- Abno
- Gene target:
- AFF3 Pre-design Chimera RNAi
Related genes to: AFF3 Pre-design Chimera RNAi
- Gene:
- AFF3 NIH gene
- Name:
- AF4/FMR2 family member 3
- Previous symbol:
- LAF4
- Synonyms:
- MLLT2-like
- Chromosome:
- 2q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-27
- Date modifiied:
- 2016-10-05
Related products to: AFF3 Pre-design Chimera RNAi
Related articles to: AFF3 Pre-design Chimera RNAi
- It is necessary for naïve CD8 T cells to be actively maintained in a quiescent metabolic state in order to respond robustly to infection while avoiding inappropriate activation during homeostasis. With age this quiescent state is lost and the CD8 T cell response to infection decreases. The factors regulating metabolic quiescence of CD8 T cells and how this regulation is lost during aging are not completely understood. Herein, we identify the transcription factor AFF3 as a regulator of metabolic quiescence in naïve CD8 T cells. While naïve AFF3 deficient CD8 T cells are more metabolically active prior to infection, they have reduced accumulation in response to viral infection, and this is correlated with a poor capacity to engage glycolysis. During aging in both murine and human CD8 T cells, AFF3 expression is decreased. In mice, this is associated with a loss of metabolic quiescence and reduced capacity to accumulate following infection. Our data highlight the role of metabolic regulation in CD8 T cell quiescence and identifies a transcription factor that may be a target to reinvigorate CD8 T cell responses during aging. - Source: PubMed
Publication date: 2026/06/23
Lumnitzer Molly EValbon Stefanie FCondotta Stephanie ANorlander Allison ELiu ShengWan JunRicher Martin J - Ossifying fibromyxoid tumor (OFMT) is a rare mesenchymal neoplasm of uncertain lineage of differentiation driven by a broad spectrum of gene fusions. It manifests primarily in soft tissues of the extremities. In this study, we performed a comprehensive clinicopathological, molecular-genetic, and epigenetic analysis of 70 cases of OFMT, with a specific focus on rare fusion subtypes, particularly ZC3H7B::BCOR, PHF1::TFE3 and MEAF6::PHF1. In addition, we included seven tumors with novel fusions, namely AFF3::PHF1, PHF1::KLF15, PHF1::PRKAG1, CREBBP::PHF1, EPC1::BMI1, MEAF6::BCOR, and EP300::BCORL1. The clinicopathological characteristics revealed a correlation between specific fusions and aggressive clinical behavior; notably, tumors with ZC3H7B::BCOR fusions were always classified as morphologically atypical or malignant and were associated with significantly higher recurrence and metastatic rates compared to other fusion groups, particularly EP400::PHF1. Immunohistochemical analysis further revealed a distinct immunophenotype in the ZC3H7B::BCOR group. While immunopositivity for cytokeratins and myogenic markers was observed in approximately one-quarter and more than one-third of OFMT cases overall, respectively, ZC3H7B::BCOR-rearranged tumors were negative for both. In contrast, the majority showed immunopositivity for pan-Trk. Additionally, DNA methylation profiling distinguished ZC3H7B::BCOR-rearranged cases from other fusion-positive OFMT, whereas the former clustered closely with a subset of high-grade endometrial stromal sarcomas. This study supports the recognition of ZC3H7B::BCOR-positive tumors as a distinct clinicopathological entity, contributing to the refined molecular taxonomy of this neoplasm. - Source: PubMed
Publication date: 2026/06/16
Klubíčková NatálieDermawan Josephine KAmeline BaptisteMartínek PetrVaněček TomášHájková VeronikaPtáková NikolaGrossmann PetrŠteiner PetrKormunda StanislavPerret Raul ELe Loarer FrançoisDehner CarinaTorres-Mora JorgeGross John MChrisinger John S ACharville GregoryKosemehmetoglu KemalWangsiricharoen SintawatMeis JeanneŠpůrková ZuzanaZámečník MichalZambo Iva StaniczkováKlinger Tomᚊvajdler MariánKinkor ZdeněkMichalová KvětoslavaBaumhoer DanielMichal MichalAntonescu Cristina RMichal Michael - Tuberculosis (TB) is a severe respiratory illness that can lead to opportunistic infections in individuals with weakened immune systems. Accurate diagnosis and monitoring of treatment responses are essential. In this study, we analyzed the miRNA and mRNA profiles of 12 patients with active TB (ATB) before and after treatment. - Source: PubMed
Publication date: 2026/06/03
Park HeechulLee Eun JuPark SunyoungPark Sung-BaeKang Yun-JeongLee JiyoungWhang JakeKang Young AeKim SunghyunLee HyejonKim Jungho - KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL), particularly in infants, represents one of the most aggressive pediatric hematological malignancies with a historically dismal prognosis. While KMT2A-AFF1 (t(4;11)) is the most prevalent fusion, a diverse array of partner genes exists, each conferring distinct biological and clinical features. This review focuses on the rare but clinically significant KMT2A-AFF3 subtype, which arises from the t(2;11)(q11.2;q23) chromosomal translocation. This review summarizes the molecular pathogenesis driven by the KMT2A-AFF3 fusion oncoprotein, which functions as an aberrant transcriptional complex. This complex hijacks essential epigenetic machinery, including the recruitment of DOT1L and interaction with Menin, leading to pathogenic histone modifications (e.g., H3K79 hypermethylation) and the subsequent upregulation of critical target genes, notably the HOXA cluster and MEIS1, thereby enforcing a B-lymphoid differentiation arrest at the pro-B/pre-B stage. Clinically, KMT2A-AFF3 ALL is characterized by high-risk features, including infant onset, hyperleukocytosis, central nervous system (CNS) involvement, and a distinct CD10-negative immunophenotype. This review highlights the evidence defining its poor prognosis, which is primarily driven by profound chemoresistance to conventional therapies, including glucocorticoids. Finally, we discuss the rapidly evolving therapeutic landscape, detailing the limitations of standard intensive chemotherapy and the immense promise of novel targeted strategies, such as Menin inhibitors (e.g., Revumenib), DOT1L inhibitors, and immunotherapies (e.g., CAR-T cells, Blinatumomab), which hold the potential to revolutionize outcomes for this high-risk leukemia subtype. - Source: PubMed
Publication date: 2025/11/26
Zhang YaweiLiang Juan - A major challenge to global vector control efforts is the increasing resistance of Aedes mosquitoes to conventional insecticides. Since they are the main vectors of dengue, Zika, and chikungunya, sustainable and environmentally friendly approaches are essential for vector control. Attractive toxic sugar baits (ATSBs) take advantage of mosquitoes' propensity for sugar and can offer an alternative strategy. However, further research is needed to investigate the performance of ATSBs, especially in determining and assessing attractant combinations that might increase mosquito attraction and feeding efficiency. - Source: PubMed
Publication date: 2026/01/05
Ayub Noor MuokhniKassim Nur Faeza AbuSabar SumiyyahHashim Nur AidaLalung JaparengSulaiman Shaida FarizaAbuelmaali Sara AWebb Cameron E